Allarity Therapeutics Reports Q1 2026 Financial Results with Increased Revenue and Net Loss

Allarity Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a modest increase in revenue and a continued focus on research and development. The company generated $25,000 in license revenue during the three months ended March 31, 2026, compared to no revenue in the same period last year. Despite this revenue, Allarity recorded a net loss of $2.75 million, slightly higher than the $2.73 million loss reported in the first quarter of 2025. The loss per share improved to $0.17 from $0.25 year-over-year, reflecting a decrease in operating expenses.

Total operating expenses for the quarter decreased to $2.71 million from $3.04 million in the prior year, primarily due to reduced research and development costs associated with the Phase II clinical trial of stenoparib. Research and development expenses fell to $1.30 million from $1.40 million, while general and administrative expenses also saw a decline, dropping to $1.42 million from $1.63 million. The company attributed these reductions to cost management efforts, including a decrease in legal fees.

In terms of liquidity, Allarity reported cash and restricted cash totaling $29.81 million as of March 31, 2026, an increase from $27.70 million at the end of the previous fiscal year. The company executed significant financing activities during the quarter, including a $20 million promissory note agreement with Streeterville Capital, which contributed to a net cash inflow of $19.74 million from financing activities. This financing is expected to support ongoing research and development efforts, particularly for stenoparib, as the company anticipates substantial expenses in the coming months.

Allarity's operational metrics indicate a strategic focus on advancing its drug development pipeline. The company has continued to invest in its proprietary Drug Response Predictor (DRP®) technology, which aims to enhance the precision of cancer treatments. As of March 31, 2026, Allarity had an accumulated deficit of $132.9 million, reflecting its ongoing investment in research and development. The company remains committed to advancing stenoparib through clinical trials and pursuing regulatory approvals, although it acknowledges the need for additional capital to fund these initiatives.

Looking ahead, Allarity expects to incur significant expenses as it continues its clinical development programs and prepares for potential commercialization of its drug candidates. The company has indicated that it may seek additional funding through equity offerings or other financing arrangements to support its operations. While management believes that its current cash position is sufficient to fund operations for at least the next twelve months, it recognizes the inherent uncertainties and risks associated with the biotechnology industry, including the need for successful clinical trials and regulatory approvals.